The dual effect of PPARα both promoting tumor cell growth and inhibiting anticancer immunity is supported by preclinical experiments in which Ppara deficiency in either implanted tumor cells or recipient host reduced tumor growth in vivo, while Ppara deficiency in both implanted tumor cells and recipient host resulted in significantly greater tumor inhibition than in either compartment alone (14). Here, PPARA is linked to neoplasm.